Common blood pressure drug linked to breast cancer recurrence

Thursday, April 28, 2011

Common blood pressure drug linked to breast cancer recurrence

Recently study by researchers at the Jonsson Comprehensive Cancer Center at UCLA, California shows that ACE inhibitors and beta blockers for high blood pressure drugs may work differently in the breast cancer microenvironment. The study published online in the journal Breast Cancer Research and Treatment, explained that ACE inhibitors which commonly used to control high blood pressure and heart failure in women and beta blockers have opposite effects for women with a personal history of breast cancer.

Researchers have used mice with breast cancer that will be used to determine the effects of chronic stress on breast cancer recurrence. The stress releases hormones will lower the immune system and cause increased the risk of tumor recurrence. The mice with breast cancer and chronically stressed had a thirty fold increased risk for breast cancer recurrence. The mice subsequently given the meta-blockers and the effects of stress on breast cancer recurrence were ameliorated. Researchers will then use the results of the study to examine the impact of the same drug in women with breast cancer.

Dr. Patricia Ganz, director of cancer prevention and control research at UCLA's Jonsson Cancer Center and first author of the study, will conduct comprehensive research on larger groups of women with breast cancer and reassure the explanation of pathways and biologic which might discovered to explain why ACE inhibitors increase the risk for breast cancer recurrence.

Inflammation seems to be an important role in breast cancer and different classes of drugs may affect different pathways of inflammation.The breast cancer patients or those at high risk for breast cancer should declare this to their doctor for other options for drugs.